Disease · MONDO_0020108
Targets91
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 91
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| BTK | Tyrosine-protein kinase BTK | 5 | Tyrosine-protein kinase BTK inhibitor | Phase 3 | https://conductscience.org/library/genes/695 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 5 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Unknown | https://conductscience.org/library/genes/1441 | Drugs and targets |
| EPOR | Erythropoietin receptor | 3 | Erythropoietin receptor agonist | Unknown | https://conductscience.org/library/genes/2057 | Drugs and targets |
| FCGRT | IgG receptor FcRn large subunit p51 | 3 | IgG receptor FcRn large subunit p51 antagonist; IgG receptor FcRn large subunit p51 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/2217 | Drugs and targets |
| ADRM1 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/11047 | Drugs and targets |
| PSMA1 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5682 | Drugs and targets |
| PSMA2 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5683 | Drugs and targets |
| PSMA3 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5684 | Drugs and targets |
| PSMA4 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5685 | Drugs and targets |
| PSMA5 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5686 | Drugs and targets |
| PSMA6 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5687 | Drugs and targets |
| PSMA7 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5688 | Drugs and targets |
| PSMA8 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/143471 | Drugs and targets |
| PSMB1 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5689 | Drugs and targets |
| PSMB10 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5699 | Drugs and targets |
| PSMB11 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/122706 | Drugs and targets |
| PSMB2 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5690 | Drugs and targets |
| PSMB3 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5691 | Drugs and targets |
| PSMB4 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5692 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020108/targets